Bionano Genomics, Inc. (NASDAQ:BNGO – Get Free Report) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totalling 4,770,000 shares, an increase of 15.2% from the August 15th total of 4,140,000 shares. Based on an average trading volume of 1,110,000 shares, the short-interest ratio is presently 4.3 days. Approximately 15.7% of the company’s shares are short sold.
Institutional Trading of Bionano Genomics
Several large investors have recently made changes to their positions in BNGO. Merit Financial Group LLC acquired a new stake in Bionano Genomics in the 1st quarter worth approximately $28,000. Bayesian Capital Management LP acquired a new position in Bionano Genomics in the 2nd quarter valued at $29,000. Allspring Global Investments Holdings LLC bought a new position in Bionano Genomics in the 1st quarter worth $34,000. Osaic Holdings Inc. lifted its position in Bionano Genomics by 5.1% during the 2nd quarter. Osaic Holdings Inc. now owns 61,649 shares of the company’s stock worth $38,000 after acquiring an additional 2,984 shares during the last quarter. Finally, Brinker Capital Investments LLC bought a new stake in Bionano Genomics during the first quarter valued at about $41,000.
Wall Street Analysts Forecast Growth
Separately, BTIG Research increased their target price on shares of Bionano Genomics to $10.00 and gave the stock a “buy” rating in a research report on Thursday, August 10th.
Bionano Genomics Stock Performance
Shares of NASDAQ BNGO remained flat at $3.00 during trading hours on Tuesday. The company had a trading volume of 504,305 shares, compared to its average volume of 882,473. The company’s 50 day moving average price is $5.27 and its 200-day moving average price is $7.31. Bionano Genomics has a 1-year low of $2.93 and a 1-year high of $30.10. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.69 and a current ratio of 3.66.
Bionano Genomics (NASDAQ:BNGO – Get Free Report) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.34). The business had revenue of $8.66 million for the quarter, compared to analyst estimates of $8.11 million. Bionano Genomics had a negative return on equity of 59.97% and a negative net margin of 464.96%. On average, research analysts predict that Bionano Genomics will post -3.5 earnings per share for the current fiscal year.
About Bionano Genomics
Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight.
- Five stocks we like better than Bionano Genomics
- What is the NASDAQ Stock Exchange?
- Hold-It-Forever AutoZone Pulls into Buy Zone
- Energy and Oil Stocks Explained
- Virtual Riches: 3 Stocks Leading the VR Revolution
- What is the S&P/TSX Index?
- 5 eCommerce Companies that need to be on Your Watch List
Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.